Similar articles

• It is not time to stop progesterone receptor testing in breast cancer.

  Colomer R, Beltran M, Dorcas J, Cortes-Funes H, Hornedo J, Valentin V, Vargas C, Mendiola C, Ciruelos E. Colomer R, et al. J Clin Oncol. 2005 Jun 1;23(16):3868-9; author reply 3869-70. doi: 10.1200/JCO.2005.05.203. J Clin Oncol. 2005. PMID: 15923595 No abstract available.
• [Estrogen and progesterone receptors in breast cancer].

  Sonoo H. Sonoo H. Nihon Rinsho. 2000 Apr;58 Suppl:146-53. Nihon Rinsho. 2000. PMID: 11025988 Review. Japanese. No abstract available.
• Prognostic factors for breast cancer and their use in the clinical setting.

  Kapoor A, Vogel VG. Kapoor A, et al. Expert Rev Anticancer Ther. 2005 Apr;5(2):269-81. doi: 10.1586/14737140.5.2.269. Expert Rev Anticancer Ther. 2005. PMID: 15877524 Review.
• Time to stop progesterone receptor testing in breast cancer management.

  Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, Lesperance ML. Olivotto IA, et al. J Clin Oncol. 2004 May 1;22(9):1769-70. doi: 10.1200/JCO.2004.99.251. J Clin Oncol. 2004. PMID: 15118010 No abstract available.
• Time for reappraisal of progesterone-receptor testing in breast cancer management.

  MacGrogan G, de Mascarel I, Sierankowski G, Mauriac L, Debled M, Durand M, De Lara CT, Avril A, Picot V, Mathoulin-Pélissier S. MacGrogan G, et al. J Clin Oncol. 2005 Apr 20;23(12):2870-1; author reply 2871. doi: 10.1200/JCO.2005.05.241. J Clin Oncol. 2005. PMID: 15838009 No abstract available.